|
|
|
|
|
|
|
|
|
|
|
|
|
SECURITIES AND EXCHANGE
COMMISSION
|
||
FORM 8-K |
||
|
CURRENT
REPORT
|
||
|
PURSUANT TO SECTION 13
OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
||
|
Date of report:
April 21, 2000
Date of earliest event reported: April 11, 2000 |
||
|
PFIZER INC.
(Exact name of registrant as specified in its charter) |
||
|
Delaware
(State or other jurisdiction of incorporation) |
1-3619
(Commission File Number) |
13-5315170
(I.R.S. Employer Identification No.) |
|
235 East 42nd Street
New York, New York (Address of principal executive offices) |
10017 (Zip Code) |
|
|
Registrant's telephone
number, including area code:
(212) 573-2323 |
||
Item 5. Other EventsOn April 11, 2000, Pfizer Inc. entered into an Asset Purchase and Sale Agreement in connection with the sale of its RID line of lice-control products. The sale of RID is subject to necessary regulatory approvals and is expected to close in the second quarter of 2000. The effects of the transaction will not be material to the operating results of Pfizer. |
||
SIGNATUREUnder the requirements
of the Securities Exchange Act of 1934, the registrant has caused
this report to be signed on its behalf by the authorized undersigned.
|
PFIZER INC. |
|
| Dated: April 21, 2000 |
By: /s/ MARGARET M. FORAN |
|
|